Blay, J.-Y., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., … Demetri, G. D. (2012). Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (>= 24 months) overall survival results. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Blay, Jean-Yves, Sant P. Chawla, Isabelle Ray-Coquard, Axel Le Cesne, Arthur P. Staddon, Mohammed M. Milhem, Nicolas Penel, et al. “Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (>= 24 months) overall survival results.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Blay J-Y, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, et al. Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (>= 24 months) overall survival results. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.

Blay, Jean-Yves, et al. “Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (>= 24 months) overall survival results.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.

Blay J-Y, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Binh BN, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing DA, Song Y, Ebbinghaus S, Haluska FG, Dodion PF, Demetri GD. Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (>= 24 months) overall survival results. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.